Capricor Therapeutics Inc
CAPR
Get informed when a big investor buys or sells
+ FollowMarket Cap$235.22M
Close$
$5.81
37.9% upside
Current Fair Value
37.9% upsideUndervalued by 37.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $235.22 Million |
|---|---|
| Enterprise Value | $82.35 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.26 |
| Beta | 0.53 |
| Outstanding Shares | 57,434,267 |
Return
| Return on Equity | -16.58% |
|---|---|
| Return on Assets | -11.07% |
| Return on Invested Capital | -12.82% |
Valuation & Multiples
| P/E Ratio | -1.76 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | 0.0 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.91 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 1.25 |
| Debt to Equity | 0.42 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-0.59
Average shareholder expectationRevenue Estimate
$2.08 M
Average shareholder expectationNext Earnings Call
Expected Date
November 17, 2026
EPS Estimate
$0.11
Average shareholder expectationRevenue Estimate
$48.20 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.4444▼ 37.35% |
|---|---|
| Total Calls | 3,385,731▼ 9.37% |
| Total Puts | 1,504,578▼ 50.76% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 58.90%▲ 2.76% |
|---|---|
| Total Invested | $1.03B▲ 29.94% |
| Investors Holding | 195▲ 45.00% |
ESG Score
No data
About Capricor Therapeutics Inc
CEO: Linda Marban